Raphael Pharmaceutical Q2 2026 net loss narrows 31% to $223,000; reports no revenue

Raphael Pharmaceutical posted a GAAP net loss of $223,000 for Q2 2026, narrowing 31% from the prior-year quarter.

Operating loss narrowed 37% to $199,000, on lower research and development spending and reduced general and administrative costs.

Research and development expenses fell 72% to $40,000; general and administrative expenses slipped 9% to $159,000.

Financial expense more than doubled to $24,000, driven by a risk premium on a related-party loan and exchange-rate differences.

The company reported no revenue for the quarter.

Cash and cash equivalents totaled $1,000 at June 30, 2026. Management flagged substantial doubt about the company’s going-concern status within one year.